101.06MMarket Cap-1348P/E (TTM)
2.900High2.650Low115.30KVolume2.690Open2.690Pre Close315.41KTurnover1.85%Turnover RatioLossP/E (Static)37.43MShares12.74052wk High0.38P/B16.88MFloat Cap2.63052wk Low--Dividend TTM6.25MShs Float12.740Historical High--Div YieldTTM9.29%Amplitude2.630Historical Low2.735Avg Price1Lot Size
Metagenomi Technologies, LLC Stock Forum
Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months
Metagenomi (Nasdaq: MGX) has announced promising 12-month durability data for its lead hemophilia A program, MGX-001.
The preclinical study in nonhuman primates (NHPs) demonstrated durable Factor VIII (FVIII) activity levels through twelve months, with two NHPs showing normal/near-normal levels (82% and 41%...
Metagenomi Presents AI-Enabled Advancements of SMART Editing Platform at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference
Metagenomi (Nasdaq: MGX) presented advancements in its AI-enabled SMART Editing Platform at the CRISPR Frontiers Conference. The company showcased AI-generated compact SMART nucleaseswith robust genome editing activity in mammalian cells. These tools, fitting within size-constrained delivery technologies, may ena...
No comment yet